You are here: Home > Institute of Excellence (CPD) > CPD Events > Corneal Therapeutics & Periocular Lesions: Green Lights & Red Flags

Corneal Therapeutics & Periocular Lesions: Green Lights & Red Flags

Date: 7/09/2022 (AEST)

Venue: Zest Waterfront Venues, 237 Spit Road Mosman, NSW, 2088

Provider: Forest Eye Surgery

Contact: Dana Robaei, [E] info@foresteyesurgery.com.au, [P] 0422 128 763

Learning Objectives

  • Gain an appreciation of the presentation and spectrum of periocular lesions
  • Identify clinical ‘red flags’ that suggest malignancy and should prompt specialist referral
  • Gain an understanding of treatment options and future trends in treating periocular tumours
  • Appreciate the anatomical constraints and special considerations in periocular reconstruction
  • To gain an in-depth understanding of neurotrophic keratitis, its clinical features, common causes, and management, including the role of Cenegermin eye drops.
  • To be updated on the latest treatments for Fuchs’ corneal endothelial dystrophy including non-surgical options such as ROCK inhibitors and future of cell therapy.
  • To develop knowledge of the latest treatment option for severe dry eye disease, including an algorithm for prescribing ciclosporin eye drops in the optometric setting

Max CPD hours awarded: 1.5

Session Information

Name
Periocular Lesions: Green Lights & Red Flags
Clinical?
Yes
Interactive?
No
Therapeutic?
Yes
Duration of CPD Session/Module
0.5
Duration of CPD Session/Module inclusive of Assessment Component
0.75
Name
Corneal Therapeutics
Clinical?
Yes
Interactive?
No
Therapeutic?
Yes
Duration of CPD Session/Module
0.5
Duration of CPD Session/Module inclusive of Assessment Component
0.75

Acknowledgement of Country

In the spirit of reconciliation Optometry Australia acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respects to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.